Jenscare Scientific's (HKG:9877) attributable loss narrowed 52% to 177.5 million yuan in 2024 from 371.7 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.
Loss per share at the pharmaceutical company narrowed 52% to 0.43 yuan from 0.89 yuan in the previous year.
Jenscare did not disclose revenue for both 2024 and 2023.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.